APOL1-Maze

Recruiting
99 years or below
All
Phase N/A
10 participants needed
1 Location

Brief description of study

MZE829-201 is a Phase 2, open-label study of MZE829 in adults aged 18 to 65 years with proteinuric chronic kidney disease (CKD) and the APOL1 high risk genotype, or APOL1 Kidney Disease (AKD). It aims to evaluate the safety and tolerability of MZE829 in adults with proteinuric AKD, to evaluate the change in albuminuria after treatment with MZE829, and to characterize the plasma pharmacokinetics of MZE829.

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 13 Mar 2026. Study ID: 25-2291

Find a site

We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team


Email

View email

Phone

Phone country flag

View phone
Investigator Avatar

Primary Contact

First name*
Last name*
Email*
Phone number*
Preferred way of contact
Please provide your preferred way of contact
Other language

Interested in the study

Select a study center that’s convenient for you, and get in touch with the study team.

Contact a study center